deferasirox has been researched along with Iron Metabolism Disorders in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kondo, T; Miyake, Z; Nakamagoe, K; Tamaoka, A; Yoshida, K | 1 |
| Aburakawa, Y; Kimura, T; Kono, S; Kuroda, K; Miyajima, H; Suzuki, Y; Terada, T; Yahara, O; Yoshida, K | 1 |
| Bardou-Jacquet, E; Beaumont-Epinette, MP; Ben Ali, Z; Brissot, P; Jouanolle, AM; Loreal, O | 1 |
| Grodde, T; Habeck, JO; Kirchhof, K; Lindner, U; Schleithoff, L; Schuppan, D; Stoelzel, U | 1 |
| Bhathal, P; Doyle, A; Rusli, F | 1 |
| Al-Ali, HK; Albrecht, S; Altamura, S; Bug, G; de Haas, K; Hubert, K; Jaekel, N; Kröger, N; Leismann, O; Lieder, K; Muckenthaler, MU; Niederwieser, D; Platzbecker, U; Stadler, M | 1 |
| Bell, S; Calder, GL; Lee, MH; MacIsaac, RJ; Sachithanandan, N; Zeimer, H | 1 |
| Bakry, R; Bonn, G; Bösch, S; Creus, M; Finkenstedt, A; Gasser, BI; Höfner, E; Janecke, AR; Kremser, C; Moser, P; Poewe, W; Schocke, M; Schranz, M; Theurl, M; Vogel, W; Wolf, E; Zoller, H | 1 |
3 review(s) available for deferasirox and Iron Metabolism Disorders
| Article | Year |
|---|---|
Deferasirox Might Be Effective for Microcytic Anemia and Neurological Symptoms Associated with Aceruloplasminemia: A Case Report and Review of the Literature.
Topics: Adult; Anemia, Iron-Deficiency; Ceruloplasmin; Copper; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Male; Middle Aged; Neurodegenerative Diseases; Treatment Outcome; Young Adult | 2020 |
Non-HFE hemochromatosis: pathophysiological and diagnostic aspects.
Topics: Alcohol Drinking; Benzoates; Biopsy; Cataract; Cation Transport Proteins; Decision Trees; Deferasirox; Diet; Gaucher Disease; Genetic Testing; Hemochromatosis; Hemochromatosis Protein; Hepcidins; Histocompatibility Antigens Class I; Humans; Inflammation; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Iron Overload; Liver; Macrophage Activation Syndrome; Magnetic Resonance Imaging; Membrane Proteins; Metabolic Syndrome; Mutation; Phlebotomy; Receptors, Transferrin; Transferrin; Triazoles | 2014 |
Aceruloplasminaemia: a rare but important cause of iron overload.
Topics: Adult; Benzoates; Ceruloplasmin; Chelation Therapy; Deferasirox; Disease Progression; Early Diagnosis; Ferritins; Humans; Iron Chelating Agents; Iron Metabolism Disorders; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Neurodegenerative Diseases; Treatment Outcome; Triazoles | 2015 |
1 trial(s) available for deferasirox and Iron Metabolism Disorders
| Article | Year |
|---|---|
Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Allografts; Benzoates; Cyclosporine; Deferasirox; Female; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Iron; Iron Metabolism Disorders; Male; Middle Aged; Prospective Studies; Triazoles | 2016 |
4 other study(ies) available for deferasirox and Iron Metabolism Disorders
| Article | Year |
|---|---|
Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation.
Topics: Administration, Oral; Benzoates; Ceruloplasmin; Deferasirox; Humans; Iron Chelating Agents; Iron Metabolism Disorders; Male; Middle Aged; Mutation; Neurodegenerative Diseases; Treatment Outcome; Triazoles | 2013 |
Aceruloplasminaemia: a family with a novel mutation and long-term therapy with deferasirox.
Topics: Adult; Benzoates; Blood Glucose; Ceruloplasmin; Chelating Agents; Chromosomes, Human, Pair 3; Deferasirox; Female; Germany; Humans; Iron; Iron Metabolism Disorders; Liver; Magnetic Resonance Imaging; Male; Mutation; Neurodegenerative Diseases; Pedigree; Treatment Outcome; Triazoles | 2015 |
Aceruloplasminaemia: a disorder of diabetes and neurodegeneration.
Topics: Adult; Benzoates; Brain; Ceruloplasmin; Copper; Deferasirox; Diabetes Mellitus, Type 2; Diagnosis, Differential; Ferritins; Humans; Insulin; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Magnetic Resonance Imaging; Male; Neurodegenerative Diseases; Triazoles | 2017 |
Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.
Topics: Antimicrobial Cationic Peptides; Benzoates; Brain; Ceruloplasmin; Consanguinity; Deferasirox; Female; Hepcidins; Homozygote; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Liver; Male; Middle Aged; Mutation; Neurodegenerative Diseases; Pedigree; RNA, Messenger; Triazoles | 2010 |